<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547257</url>
  </required_header>
  <id_info>
    <org_study_id>CP022</org_study_id>
    <nct_id>NCT04547257</nct_id>
  </id_info>
  <brief_title>Safety &amp; Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19</brief_title>
  <acronym>CP022</acronym>
  <official_title>Safety and Effectiveness Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the Treatment of Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ExThera Medical Europe BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ExThera Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vivantes Klinikum Neukölln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ExThera Medical Europe BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Effectiveness Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph&#xD;
      100) in the treatment of patients with COVID-19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, randomized, controlled clinical investigation designed to&#xD;
      evaluate the safety and effectiveness of the Exthera Medical Seraph 100 Microbind Affinity&#xD;
      Blood Filter in the treatment of patients with confirmed SARS-CoV-2 infection.&#xD;
&#xD;
      The clinical investigation will be conducted at 3 centers in Germany and at 2 centers in&#xD;
      Spain. Subjects will be randomized to the treatment group (Seraph 100 + standard of care)&#xD;
      versus control group (standard of care only).&#xD;
&#xD;
      Subjects will be followed for 28 days. For RT-PCR study related blood drawn will take place&#xD;
      immediately before treatment with Seraph 100 starts in the treatment group or immediately&#xD;
      after randomization into the control group. Additionally, at timepoint 15 minutes, 45&#xD;
      minutes, 2 hours, 6 hours, 12 hours, 24 hours, 36 hours, 48 hours, and 96 hours are&#xD;
      applicable for both treatment and control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The primary objective is to demonstrate the safety and effectiveness of the Exthera Medical Seraph 100 Microbind Affinity Blood Filter in the clinical improvement of SARS-CoV-2 infected patients, measured by the reduction of established and suspected prognostic parameters.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Organ failure</measure>
    <time_frame>48 hours after treatment</time_frame>
    <description>Change in organ failure as assessed by a modified Sequential Organ Failure Assessment score (range, 0-20, with higher scores indicating more dysfunction) from baseline to 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Organ Failure</measure>
    <time_frame>During ICU stay at 12 hours, 24 hours, 36 hours, 96 hours after treatment</time_frame>
    <description>Change in organ failure as assessed by a modified Sequential Organ Failure Assessment score (range 0 - 20, with higher scores indicating more dysfunction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>28 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ dysfunction-free days</measure>
    <time_frame>Daily during ICU stay (up to 28 days)</time_frame>
    <description>Organ dysfunction-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit (ICU) complications</measure>
    <time_frame>Daily during ICU stay (up to 28 days)</time_frame>
    <description>Intensive Care Unit (ICU) complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days (VFDs)</measure>
    <time_frame>Daily during ICU stay (up to 28 days)</time_frame>
    <description>Ventilator-free days (VFDs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay (LOS) at ICU and hospital ward</measure>
    <time_frame>During ICU and hospital ward stay (up to 28 days)</time_frame>
    <description>Length of stay (LOS) at ICU and hospital ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis Factors</measure>
    <time_frame>From baseline up to 48 hours</time_frame>
    <description>Prognosis factors (D-Dimer, Troponin T, Ferritin, NTpro-BNP, LDH, IL6, sIL2)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>N (%) of patients with treatment emergent adverse events</measure>
    <time_frame>Occurrence within the 28 days follow-up period</time_frame>
    <description>N (%) of patients with treatment emergent adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory data</measure>
    <time_frame>Daily during ICU stay (up to 28 days)</time_frame>
    <description>Laboratory data (Blood test, Hematology, chemistry and coagulation)</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital signs score</measure>
    <time_frame>Daily during ICU stay (up to 28 days)</time_frame>
    <description>Vital signs score</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination score</measure>
    <time_frame>Daily during ICU stay (up to 28 days)</time_frame>
    <description>Physical examination score</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction of viral load</measure>
    <time_frame>During treatment (minimum treatment duration is 5 hours, maximum treatment duration is 24 hours)</time_frame>
    <description>Reduction of viral load</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extracorporeal therapy with Seraph 100 blood filter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients receive antibiotics only as standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Seraph 100</intervention_name>
    <description>Bloodfiltration with Seraph 100</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with confirmed SARS-CoV-2 infection&#xD;
&#xD;
          2. Be ≥ 18 years old and ≤90 years old&#xD;
&#xD;
          3. Acute respiratory distress syndrome assessed by a modified Sequential Organ Failure&#xD;
             Assessment score of at least 2 points&#xD;
&#xD;
          4. At least one additional organ dysfunction assessed by a modified Sequential Organ&#xD;
             Failure Assessment score of at least 1 point&#xD;
&#xD;
          5. Written or electronic consent of the subjects who are legally competent and have the&#xD;
             capacity to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is currently participating in another clinical investigation&#xD;
&#xD;
          2. Pregnant or nursing subjects and those who plan pregnancy during the clinical&#xD;
             investigation follow-up period&#xD;
&#xD;
          3. Presence of comorbid conditions, or other medical, social, or psychological conditions&#xD;
             that, in the investigator's opinion, could limit the subject's ability to participate&#xD;
             in the clinical investigation or to comply with follow-up requirements, or impact the&#xD;
             scientific soundness of the clinical investigation results&#xD;
&#xD;
          4. Have neutropenia (absolute neutrophil count &lt;500 cells/uL)&#xD;
&#xD;
          5. Have Child-Pugh Class C cirrhosis&#xD;
&#xD;
          6. Have platelet count &lt;30.000/uL&#xD;
&#xD;
          7. Contraindications for heparin sodium for injection&#xD;
&#xD;
          8. Subjects demonstrating any contraindication for this treatment as described in the IFU&#xD;
&#xD;
          9. Subjects with known allergy of polyethylene and copolyester&#xD;
&#xD;
         10. Subjects with hospital-acquired SARS-CoV-2 infections&#xD;
&#xD;
         11. Subject is held in an institution by court or official order&#xD;
&#xD;
         12. Subject is dependent on the sponsor or investigator so that consent can no longer be&#xD;
             considered voluntary&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herwig Gerlach, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vivantes Neukoelln Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carla Kikken-Jussen</last_name>
    <phone>+ 31 43 8200 399</phone>
    <email>carla@extheramedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Aschaffenburg-Alzenau</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Büttner, Dr.</last_name>
      <phone>+49 6021 320</phone>
      <email>stefan.buettner@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Büttner, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricard Ferrer Roca, Dr.</last_name>
      <phone>+34 93 489 44 20</phone>
      <email>r.ferrer@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Ricard Ferrer Roca, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Sponsor will be responsible for determining whether to register the clinical investigation on www.clinicaltrials.gov or any other clinical trials, in accordance with the International Committee of Medical Journal Editors guidelines, or any other applicable guidelines.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>in 9 months</ipd_time_frame>
    <ipd_url>http://extheramedical.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

